| On
17 February 2005 Lilly and Boehringer Ingelheim announced
that the EMEA has recommended that duloxetine (CYMBALTA)
be approved in the EU for the treatment of diabetic peripheral
neuropathic pain.
Duloxetine,
a dual noradrenaline and 5HT reuptake inhibitor, is available
in the USA for the treatment of depression and neuropathic
pain and is available in several EU countries for the treatment
of stress urinary incontinence and in the UK for depression.
Boehringer Ingelheim acquired rights to co-develop and co-commercialize
duloxetine in certain regions from Lilly, under an agreement
signed in 2002.
|
